Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 713 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PART 1: Double-blind Placebo-controlled Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 8, 2026, 1:04 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 8, 2026, 1:04 AM EDT
Terminated Phase 1 Interventional

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

NCT05956509
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
ABBV-950, BOTOX, Placebo for ABBV-950
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Carlsbad, California • Downey, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

NCT02166346
View directory record Official record
Conditions
Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 8, 2026, 1:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 8, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

NCT02466243
View directory record Official record
Conditions
Dermatomyositis
Interventions
JBT-101, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 8, 2026, 1:04 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

NCT02202213
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Lu AF11167
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Results available

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

NCT04478708
View directory record Official record
Conditions
Obesity
Interventions
maridebart cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Anaheim, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 8, 2026, 1:04 AM EDT
Terminated Phase 1 Interventional

A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

NCT01332552
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2485852 70 mg, GSK2485852 420 mg, placebo, GSK2485852 630 mg, GSK2485852 70 mg + Ritonavir 100mg, GSK2485852 210 mg +Ritonavir 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Anaheim, California • Orlando, Florida • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

NCT03633617
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
62
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

NCT00809159
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

NCT01475981
View directory record Official record
Conditions
Healthy
Interventions
JTK-853 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 8, 2026, 1:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728
View directory record Official record
Conditions
Heart Failure, Healthy Volunteer
Interventions
AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers

NCT04265456
View directory record Official record
Conditions
Postoperative Pain
Interventions
Pregabalin 100mg, Acetaminophen 1300mg
Drug
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

NCT05877053
View directory record Official record
Conditions
Healthy Participants
Interventions
CK-4021586, Placebo for CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 8, 2026, 1:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

NCT06119529
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
LY3872386, Prednisone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 8, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

NCT01501383
View directory record Official record
Conditions
Epilepsy
Interventions
VX-765 Part A, Placebo, VX-765 Part B
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
22
States / cities
Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 8, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

NCT03933488
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-994, TAK-994 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Glendale, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 8, 2026, 1:04 AM EDT